Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Operating Income Loss of -$85.31 million for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -75.1% in Operating Income Loss from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Operating Income Loss has declined by 15,208.4%.
- Historical annual values: Fiscal year 2025: -$85.31 million | Fiscal year 2024: -$48.72 million | Fiscal year 2023: -$45.08 million | Fiscal year 2022: -$39.84 million | Fiscal year 2021: -$55.99 million | Fiscal year 2020: -$122.81 million | Fiscal year 2019: -$77.10 million | Fiscal year 2018: -$56.75 million | Fiscal year 2017: -$32.56 million | Fiscal year 2016: -$19.99 million | Fiscal year 2015: -$8.85 million | Fiscal year 2014: -$2.65 million | Fiscal year 2013: -$557.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: